Brief: Effector Therapeutics Reports Positive Interim Results In Zotatifin Phase 1/2 Clinical Trial
June 5 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* POSITIVE INTERIM RESULTS IN ZOTATIFIN (EFT226) PHASE 1/2
CLINICAL TRIAL SHOWING SAFETY AND TOLERABILITY,
* TWO PARTIAL RESPONSES OBSERVED IN HEAVILY PRE-TREATED ER+
BREAST
CANCER PATIENTS
* EFFECTOR THERAPEUTICS - TREATMENT EMERGENT ADVERSE EVENTS
(TEAES) RELATED TO ZOTATIFIN WERE MOSTLY MILD, READILY MANAGED
AND REVERSIBLE
* ANTICIPATE REPORTING TOPLINE DATA FROM OUR CURRENT
EXPANSION
COHORTS BY END OF 2022
Source text for Eikon: ID:nGNXYzPYM
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright